Monoacylglycerol lipase (MAGL) as a promising therapeutic target



Downloads per month over past year

Gil Ordoñez, Ana and Martín Fontecha, Mar and Ortega Guitérrez, Silvia and López Rodríguez, María Luz (2018) Monoacylglycerol lipase (MAGL) as a promising therapeutic target. Biochemical Pharmacology, 157 . pp. 18-32. ISSN 0006-2952

[thumbnail of Mar Martin Fontecha1-s2.0-S0006295218303046-main.pdf] PDF
Restringido a Repository staff only


Official URL:


Monoacylglycerol lipase (MAGL) has been characterized as the main enzyme responsible for the inactivation of the most abundant brain endocannabinoid, 2-arachidonoylglycerol (2-AG). Besides this role, MAGL has progressively acquired a growing importance as an integrative metabolic hub that controls not only the in vivo levels of 2-AG but also of other monoacylglycerides and, indirectly, the levels of free fatty acids derived from their hydrolysis as well as other lipids with pro-inflammatory or pro-tumorigenic effects, coming from the further metabolism of fatty acids. All these functions have only started to be elucidated in the last years due to the progress made in the knowledge of the structure of MAGL and in the development of genetic and chemical tools. In this review we report the advances made in the field with a special focus on the last decade and how MAGL has become a promising therapeutic target for the treatment of several diseases that currently lack appropriate therapies.

Item Type:Article
Additional Information:

Received 29 May 2018, Accepted 25 July 2018, Available online 27 July 2018.

Uncontrolled Keywords:Monoacylglycerol lipase; MAGL; Endogenous cannabinoid system; MAGL inhibitors; Endocannabinoids2-Arachidonoylglycerol
Subjects:Sciences > Chemistry > Biochemistry
Medical sciences > Pharmacy > Pharmaceutical chemistry
ID Code:50710
Deposited On:17 Jan 2019 15:16
Last Modified:17 Jan 2019 15:16

Origin of downloads

Repository Staff Only: item control page